Live Breaking News & Updates on Paulb Manning|Page 4

Stay updated with breaking news from Paulb manning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Canaccord Genuity Group Cuts Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $7.00

Taysha Gene Therapies (NASDAQ:TSHA – Free Report) had its price objective lowered by Canaccord Genuity Group from $13.00 to $7.00 in a research report sent to investors on Wednesday morning, Benzinga reports. The firm currently has a buy rating on the stock. A number of other equities research analysts also recently commented on the stock. […] ....

United States , Paulb Manning , Seanp Nolan , Needham Company , Topco Ltd , Dynamic Advisor Solutions , Taysha Gene Therapies Inc , America Corp , Quantum Private Wealth , Cantor Fitzgerald , Canaccord Genuity Group , Geode Capital Management , Taysha Gene Therapies , Free Report , Truist Financial , Moderate Buy , Gene Therapies , Taysha Gene , Advisor Solutions , Private Wealth , Capital Management , Get Free Report , Taysha Gene Therapies Daily , Nasdaq Tsha , Lower Price Target , Canaccord Genuity Group Inc ,

Verrica Pharmaceuticals (NASDAQ:VRCA) Price Target Increased to $12.00 by Analysts at HC Wainwright

Verrica Pharmaceuticals (NASDAQ:VRCA – Free Report) had its price objective hoisted by HC Wainwright from $11.00 to $12.00 in a report issued on Thursday morning, Marketbeat.com reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Verrica Pharmaceuticals’ FY2026 earnings at $0.45 EPS. Several other equities research analysts […] ....

Nova Scotia , United States , Paulb Manning , Ted White , Securities Exchange Commission , Institutional Investors Weigh In On Verrica Pharmaceuticals , Blackrock Inc , Verrica Pharmaceuticals , Avoro Capital Advisors , Capital Management , News Ratings For Verrica Pharmaceuticals Daily , Royal Bank , Needham Company , Verrica Pharmaceuticals Stock , Verrica Pharmaceuticals Inc , Free Report , Verrica Pharmaceutical , Get Free Report , Exchange Commission , Director Paul , Capital Advisors , Pharmaceuticals Inc , Verrica Pharmaceuticals Daily , Nasdaq Vrca , Boost Price Target , Hc Wainwright ,

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Director Paul B. Manning Purchases 200,000 Shares

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Free Report) Director Paul B. Manning bought 200,000 shares of Verrica Pharmaceuticals stock in a transaction on Monday, July 24th. The stock was acquired at an average cost of $5.02 per share, for a total transaction of $1,004,000.00. Following the acquisition, the director now owns 7,851,128 shares in the […] ....

United States , Paulb Manning , Verrica Pharmaceuticals Company Profile , Institutional Trading Of Verrica Pharmaceuticals , Kovitz Investment Group Partners , Capital Management , Tower Research Capital , Verrica Pharmaceuticals Inc , Verrica Pharmaceuticals Price Performance , News Ratings For Verrica Pharmaceuticals Daily , Verrica Pharmaceuticals , Get Free Report , Director Paul , Investment Group Partners , Research Capital , Jane Street Group , Pharmaceuticals Inc , Verrica Pharmaceuticals Daily , Nasdaq Vrca , Insider Trading , Nsider Trades ,